Salutaris Medical Devices

SalutarisMD is pioneering a novel treatment paradigm for challenging retinal diseases with its BetaCurve device, a 510(k)-cleared platform for episcleral brachytherapy. The company is initially targeting polypoidal choroidal vasculopathy (PCV), a subtype of wet-AMD that responds poorly to standard anti-VEGF injections, with a one-time, 10-minute outpatient procedure. By leveraging precision beta radiation from a stable Strontium-90 source, BetaCurve aims to treat the root cause of the disease, potentially eliminating the need for lifelong, burdensome injections. SalutarisMD represents a compelling opportunity to address a significant unmet medical need in a large, underserved global patient population.

BetaCurve™: A patented, minimally invasive episcleral brachytherapy device that curves around the eye to deliver precise, low-dose beta radiation from a Strontium-90 source, guided by a fiber optic light for real-time placement.

BetaCurve's direct competitors are other novel therapies aiming to reduce injection burden in wet-AMD, including longer-acting anti-VEGF drugs (e.g., faricimab, high-dose aflibercept), gene therapies (e.g., RGX-314), and port delivery systems (e.g., Ranibizumab PDS). However, as a device delivering radiation directly to the disease site, BetaCurve is mechanistically unique and is positioned as a curative solution for specific subtypes, rather than just a longer-lasting palliative treatment.